Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
University Hospital, Basel, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)
AbbVie
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
Children's Oncology Group
Novartis
Children's Oncology Group
Acrotech Biopharma Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Albert Einstein College of Medicine
St. Jude Children's Research Hospital
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
University of Louisville
Fred Hutchinson Cancer Center
Indiana University
Barbara Ann Karmanos Cancer Institute
SillaJen, Inc.
Children's Oncology Group
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Indiana University
University of Minnesota
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University Hospital Muenster
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)